

## SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results

March 4, 2025

NEW YORK (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 11, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

A live webcast of the call will also be available on the Company's website at <a href="http://www.siga.com">http://www.siga.com</a> in the Investor Relations section of the site, or by <a href="clicking here">clicking here</a>. Please log in approximately 5-10 minutes prior to the scheduled start time.

Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1152574. The archived webcast will be available in the Investor Relations section of the <u>Company's website</u>.

## **About SIGA**

SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit <a href="https://www.siga.com">www.siga.com</a>.

## **Contacts:**

Suzanne Harnett <a href="mailto:sharnett@siga.com">sharnett@siga.com</a>

and

**Investors** 

Jennifer Drew-Bear, Edison Group <a href="mailto:Jdrew-bear@edisongroup.com">Jdrew-bear@edisongroup.com</a>

Media

Holly Stevens, Berry & Company <a href="https://hstevens@berrypr.com">hstevens@berrypr.com</a>